Exelixis
EXEL
#1707
Rank
S$16.03 B
Marketcap
S$63.78
Share price
-0.58%
Change (1 day)
10.20%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): S$4.01

According to Exelixis's latest financial reports the company's current EPS (TTM) is S$4.01. In 2025 the company made an earnings per share (EPS) of S$3.70.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$4.018.55%
2025S$3.70
2023S$0.8414.61%
2022S$0.73-22.97%
2021S$0.95100%
2020S$0.47-65.09%
2019S$1.36-53.91%
2018S$2.94333.96%
2017S$0.68-260.61%
2016S-$0.42-58.75%
2015S-$1.02-42.45%
2014S-$1.785.3%
2013S-$1.69

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
S$11.18 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$1.68-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$18.53 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
S$3.28-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$4.55 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$4.56 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$4.97 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
S-$4.70-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S-$1.07-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA